Education
About Us
Working with TipRanks
Follow Us
Corvus Pharmaceuticals Inc (CRVS)
NASDAQ:CRVS
Total Valuation
Corvus Pharmaceuticals has a market cap or net worth of $278.38M. The enterprise value is $294.22M.
Market Cap$278.38M
Enterprise Value$294.22M
Share Statistics
Corvus Pharmaceuticals has 77,114,640 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding77,114,640
Owned by Insiders16.85%
Owned by Institutions29.80%
Financial Efficiency
Corvus Pharmaceuticals’s return on equity (ROE) is -1.91 and return on invested capital (ROIC) is -82.22%.
Return on Equity (ROE)-1.91
Return on Assets (ROA)-0.90
Return on Invested Capital (ROIC)-82.22%
Return on Capital Employed (ROCE)-0.82
Revenue Per Employee0.00
Profits Per Employee-2.01M
Employee Count31
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Corvus Pharmaceuticals is -5.24. Corvus Pharmaceuticals’s PEG ratio is 0.75.
PE Ratio-5.24
PS Ratio0.00
PB Ratio9.30
Price to Fair Value10.02
Price to FCF-11.87
Price to Operating Cash Flow-11.91
PEG Ratio0.75
Income Statement
In the last 12 months, Corvus Pharmaceuticals had revenue of 0.00 and earned -62.29M in profits. Earnings per share was -1.02.
Revenue0.00
Gross Profit0.00
Operating Income-27.55M
Pretax Income-62.29M
Net Income-62.29M
EBITDA-27.55M
Earnings Per Share (EPS)-1.02
Cash Flow
In the last 12 months, operating cash flow was -25.42M and capital expenditures 0.00, giving a free cash flow of -25.42M billion.
Operating Cash Flow-25.42M
Free Cash Flow-25.42M
Free Cash Flow per Share-0.33
Dividends & Yields
Corvus Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.30
52-Week Price Change58.33%
50-Day Moving Average3.64
200-Day Moving Average5.28
Relative Strength Index (RSI)50.22
Average Volume (3m)1.34M
Important Dates
Corvus Pharmaceuticals upcoming earnings date is Aug 12, 2025, TBA Not Confirmed.
Last Earnings DateMay 8, 2025
Next Earnings DateAug 12, 2025
Ex-Dividend Date―
Financial Position
Corvus Pharmaceuticals as a current ratio of 1.54, with Debt / Equity ratio of 3.45%
Current Ratio1.54
Quick Ratio1.54
Debt to Market Cap0.00
Net Debt to EBITDA0.28
Interest Coverage Ratio-15.10
Taxes
In the past 12 months, Corvus Pharmaceuticals has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Corvus Pharmaceuticals EV to EBITDA ratio is -11.57, with an EV/FCF ratio of -12.53.
EV to Sales0.00
EV to EBITDA-11.57
EV to Free Cash Flow-12.53
EV to Operating Cash Flow-12.53
Balance Sheet
Corvus Pharmaceuticals has $51.96M in cash and marketable securities with $1.12M in debt, giving a net cash position of -$50.84M billion.
Cash & Marketable Securities$51.96M
Total Debt$1.12M
Net Cash-$50.84M
Net Cash Per Share-$0.66
Tangible Book Value Per Share$0.53
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Corvus Pharmaceuticals is $13.33, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$13.33
Price Target Upside269.25% Upside
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast―
EPS Growth Forecast-71.53%